Skip to main content
Top
Published in: Neurological Sciences 8/2022

22-04-2022 | Multiple Sclerosis | Original Article

Italian translation and validation of fatigue symptoms and impacts questionnaire in relapsing multiple sclerosis (FSIQ-RMS)

Authors: Ilaria Ruotolo, Giovanni Sellitto, Antonio Ianniello, Nikolaos Petsas, Letizia Castelli, Giovanni Galeoto, Anna Berardi, Valeria Barletta, Antonella Conte, Carlo Pozzilli

Published in: Neurological Sciences | Issue 8/2022

Login to get access

Abstract

Background

Fatigue is a disabling symptom of multiple sclerosis (MS) and impacts on daily life. The Fatigue Symptoms and Impacts Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) is a new 20-item tool that investigates the aspects of fatigue in MS. It concerns motor, cognitive, social, and emotional aspects of fatigue. We aim at validating the Italian version of FSIQ-RMS in an Italian population of MS patients and demonstrate its reliability and construct validity.

Methods

We included patients with diagnosis of MS, age between 18 and 70 years with ability to participate in a 90-min interview. Each patient completed the Italian version of FSIQ-RMS and Fatigue Severity Scale (FSS) at the same time. Construct validity was explored by the exploratory factor analysis; reliability was assessed with Cronbach’s alpha; and test–retest stability was examined through intraclass correlation coefficient (ICC). Concurrent validity was calculated using Pearson’s correlation.

Results

We enrolled 171 patients (126 female and 45 male), 83% with relapsing MS (RMS), and 17% with secondary progressive MS (SPMS). Italian FSIQ-RMS showed a Cronbach’s alpha of 0.92; ICC was 0.96. Pearson’s correlation coefficient between FSIQ-RMS and FSS total score was statistically significant (p < 0.01); FSIQ-RMS inversely correlated also with BMI and positively with EDSS.

Conclusion

The Italian version of FSIQ-RMS has excellent psychometric properties and can be used in research and clinical setting to evaluate physical, cognitive, and social fatigue in both RMS and SPMS.
Literature
1.
go back to reference Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ (1994) The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci J Can Sci Neurol 21:9–14CrossRef Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ (1994) The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci J Can Sci Neurol 21:9–14CrossRef
5.
go back to reference Olascoaga J (2010) Quality of life and multiple sclerosis. Rev Neurol 51:279–288PubMed Olascoaga J (2010) Quality of life and multiple sclerosis. Rev Neurol 51:279–288PubMed
7.
go back to reference Schwid SR, Covington M, Segal BM, Goodman AD (2002) Fatigue in multiple sclerosis: current understanding and future directions. J Rehabil Res Dev 39:211–224PubMed Schwid SR, Covington M, Segal BM, Goodman AD (2002) Fatigue in multiple sclerosis: current understanding and future directions. J Rehabil Res Dev 39:211–224PubMed
8.
go back to reference Brañas P, Jordan R, Fry-Smith A, Burls A, Hyde C (2000) Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess Winch Engl 4:1–61 Brañas P, Jordan R, Fry-Smith A, Burls A, Hyde C (2000) Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess Winch Engl 4:1–61
20.
24.
go back to reference Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D’Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T (2021) Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial. JAMA Neurol 78:558. https://doi.org/10.1001/jamaneurol.2021.0405CrossRefPubMed Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D’Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T (2021) Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial. JAMA Neurol 78:558. https://​doi.​org/​10.​1001/​jamaneurol.​2021.​0405CrossRefPubMed
25.
go back to reference Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173. https://doi.org/10.1016/S1474-4422(17)30470-2CrossRefPubMed Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173. https://​doi.​org/​10.​1016/​S1474-4422(17)30470-2CrossRefPubMed
Metadata
Title
Italian translation and validation of fatigue symptoms and impacts questionnaire in relapsing multiple sclerosis (FSIQ-RMS)
Authors
Ilaria Ruotolo
Giovanni Sellitto
Antonio Ianniello
Nikolaos Petsas
Letizia Castelli
Giovanni Galeoto
Anna Berardi
Valeria Barletta
Antonella Conte
Carlo Pozzilli
Publication date
22-04-2022
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 8/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-022-06080-1

Other articles of this Issue 8/2022

Neurological Sciences 8/2022 Go to the issue